TrialESMO open2025

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

J Crown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.